Salmonella typhi TY2 VI polysaccharide antigen
Highest phase reached
Phase 3
Drug type
Unknown
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Unknown
- Drug name
- Salmonella typhi TY2 VI polysaccharide antigen
- salmonella enterica subsp enterica serovar typhi ty2 vi polysaccharide antigen
- SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHI TY2 VI POLYSACCHARIDE ANTIGEN
- salmonella typhi ty2 polysaccharide antigen a
- SALMONELLA TYPHI TY2 POLYSACCHARIDE ANTIGEN, A
- salmonella typhi ty2 vi polysaccharide antigen
- Salmonella typhi ty2 vi polysaccharide antigen
- Salmonella typhi vaccine (Typhim Vi)
- Salmonella typhi vaccine (Typhim Vi®)
- salmonella typhi vaccine typhim vi
- typhim vi
- Typhim vi
- Typhim Vi
- Typhim VI
- TYPHIM Vi (Salmonella typhi vaccine)
- typhim vi salmonella typhi vaccine
- typhim vi sanofi pasteur msd
- Typhim Vi®
- Typhim-Vi
- typhoid vi polysaccharide vaccine
- Typhoid vi polysaccharide vaccine
- TYPHOID VI POLYSACCHARIDE VACCINE [VANDF]
- typhoid vi polysaccharide vaccine s typhi ty2 strain
- typhoid vi polysaccharide vaccine vandf
- TYPHOID VI POLYSACCHARIDE VACCINE, S TYPHI TY2 STRAIN
- First in class
- No
- Orphan designation
- No
- Drug name stem
- sal-
- Condition
- Stress Disorders, Post-Traumatic
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0001358
- Subject identifier
- D013313
- Condition
- Typhoid Fever
- Highest recorded phase
- 1
- Condition identifier
- EFO:0006789
- Subject identifier
- D014435
- Condition
- Inflammation
- Highest recorded phase
- 0.5
- Condition identifier
- MP:0001845
- Subject identifier
- D007249
- Condition identifier
- EFO_0000195
- Condition identifier
- EFO_0006789
- Highest recorded phase
- 1
- Condition identifier
- EFO_0600064
- Highest recorded phase
- 1
- Condition identifier
- EFO_1001418
- Condition identifier
- EFO_1001418
- Highest recorded phase
- 4
- Condition identifier
- HP_0100806
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0000827
- Condition identifier
- MONDO_0002009
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0002050
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0006502
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0043905
- Highest recorded phase
- 1
- Event
- abortion
- Reports
- 3
- Reporting signal score
- 17.3216
- Event
- urticaria chronic
- Reports
- 3
- Reporting signal score
- 22.5586
- NCT03048929
- NCT03926455
- NCT05346302
- Prodrug
- No
- Inorganic
- No
- Natural product
- No
Related records
Trials (44)
- A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants
- Cognitive, Emotional, and Neural Responses to Acute Inflammation
- Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood
- Cross-reactive Immunity Elicited by Oral and Parenteral Typhoid Vaccines
- CVD 909 Vi Prime Boost Study
- Effects of Aging on Primary and Secondary Vaccine Responses
- Effects of Oral Iron Supplementation Before vs at Time of Vaccination on Immune Response in Iron Deficient Kenyan Women
- Effects of Oral Iron Supplementation on Vaccine Response in Iron Deficient Kenyan Women
- Effects of Oxygen Treatment on Mechanisms Involved in Ischemia-reperfusion Injury: A Pilot Study in Healthy Volunteers
- Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever
- Exploratory Study on the Mood and Cytokine Levels in Female Healthy Participants and Major Depressive Disorder Patients
- Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)
- Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)
- Immunogenicity and Tolerability of Booster Typhoid Conjugate Vaccine (TCV) 5-6 Years After Initial Dose in Children in Burkina Faso
- Inflammation and Threat Sensitivity in PTSD
- Inflammatory Challenge and Fear
In development for (6)
- Acute respiratory distress syndrome Phase 1
- Depressive disorder Phase 1
- Major depressive disorder Phase 1
- Pneumonitis Phase 1
- Post-traumatic stress disorder Early phase 1
- Typhoid fever Phase 1